Julian Symons
Chief Tech/Sci/R&D Officer at ALIGOS THERAPEUTICS, INC.
Net worth: 386 183 $ as of 31/03/2024
Profile
Julian A.
Symons is currently the Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. Prior to this, he worked as the Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Dr. Symons holds a doctorate degree from York University and an undergraduate degree from the University of Central Lancashire.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/03/2024 | 394,064 ( 0.54% ) | 386 183 $ | 31/03/2024 |
Julian Symons active positions
| Companies | Position | Start |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
Former positions of Julian Symons
| Companies | Position | End |
|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/04/2018 |
Training of Julian Symons
| York University | Doctorate Degree |
| University of Central Lancashire | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Julian Symons
